<DOC>
	<DOCNO>NCT00481481</DOCNO>
	<brief_summary>Assessment safety efficacy tacrolimus modify release ( FK506MR ) base immunosuppressive regimen stable kidney transplant subject convert cyclosporin base immunosuppressive regimen .</brief_summary>
	<brief_title>Conversion Study From Cyclosporine FK506MR Based Immunosuppression Kidney Transplant Subjects</brief_title>
	<detailed_description>Multicenter , single-arm , open phase IIIb , conversion study Cyclosporine A-based immunosuppressive regimen replace administration tacrolimus modify release formulation , MR4 , daily ( morning dose ) stable renal transplant subject . The initial recommend dose MR4 0.1 mg/kg/day . Twenty-four week treatment MR4-based immunosuppressive regimen consider appropriate study duration order ass response subject suffer one know cyclosporine side effect , hypertrichosis/hirsutism , gingival hyperplasia , hyperlipidemia , arterial hypertension . Stable , adult kidney transplant recipient ( ≥ 12 month post transplant ) currently treat cyclosporine meet Inclusion Exclusion Criteria enrol .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Serum creatinine &lt; 200 µmol/l ( &lt; 2.3 mg/dl ) enrollment . Female subject childbearing potential must negative serum pregnancy test enrollment must agree maintain effective birth control study . Capable understanding purpose risk study , fully inform give write informed consent ( sign Informed Consent obtain ) . Previously receive organ transplant kidney . Acute rejection episode within 12 week prior enrollment , acute rejection episode within 24 week prior enrollment require antilymphocyte antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Tacrolimus , Kidney Transplantation</keyword>
</DOC>